NeuroPace (NPCE) Preferred Stock Liabilities (2020 - 2021)
NeuroPace's quarterly Preferred Stock Liabilities came in at $141.4 million in Q1 2021, up 92.23% year-on-year from $73.6 million in Q1 2020, and little changed quarter-over-quarter from $141.4 million in Q4 2020.
NeuroPace has reported Preferred Stock Liabilities for 2 years, with the latest figure at $141.4 million in Q1 2021.
- For the quarter ending Q1 2021, Preferred Stock Liabilities rose 92.23% year-over-year to $141.4 million; the trailing twelve-month figure through Mar 2021 stood at $141.4 million (up 92.23% YoY), and the FY2020 full-year result was $141.4 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q1 2021 stood at $141.4 million, roughly flat from $141.4 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $141.4 million in Q3 2020, with the low at $73.5 million in Q2 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | - |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | - |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | - |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | NeuroPace | 558.86 Mn | 504.88 Mn | 18.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 141.42 Mn |
| Dec 31, 2020 | 141.42 Mn |
| Sep 30, 2020 | 141.42 Mn |
| Jun 30, 2020 | 73.45 Mn |
| Mar 31, 2020 | 73.57 Mn |